Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birinapant - Medivir AB

Next Previous
Search
Drug Profile

Birinapant - Medivir AB

Alternative Names: IGM-9427; TL-32711

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Princeton University
  • Developer IGM Biosciences; Medivir AB; National Cancer Institute (USA); University of Pennsylvania
  • Class Amides; Antineoplastics; Antivirals; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Hepatitis B; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Head and neck cancer; HIV infections; Legionella infections; Lymphoma; Non-Hodgkin's lymphoma; Pancreatic cancer; Tuberculosis

Most Recent Events

  • 20 Jan 2025 IGM Biosciences terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Spain, France, Australia, South Korea and the US (IV) (NCT04553692)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top